Equities researchers at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 6.1 %
NASDAQ EVOK opened at $0.49 on Friday. Evoke Pharma has a twelve month low of $0.41 and a twelve month high of $2.40. The company has a market cap of $4.12 million, a price-to-earnings ratio of -0.21 and a beta of 0.38. The business’s fifty day moving average is $0.57 and its 200 day moving average is $0.87.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The firm had revenue of $1.68 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to Use the MarketBeat Stock Screener
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Manufacturing Stocks Investing
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
